First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue American Journal of Transplantation Année : 2023

First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report

Résumé

Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an IgG-degrading enzyme derived from Streptococcus pyogenes, is a novel agent that has been used to convert positive crossmatches to negative in kidney transplant candidates, allowing transplantation to occur. We present the first case of imlifidase use for antibody depletion in a highly sensitized lung transplant candidate who went on to undergo a successful bilateral lung transplant.

Dates et versions

hal-04068529 , version 1 (14-04-2023)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Antoine Roux, Vincent Bunel, Natalia Belousova, Jonathan Messika, Sébastien Tanaka, et al.. First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report. American Journal of Transplantation, 2023, 23 (2), pp.294-297. ⟨10.1016/j.ajt.2022.11.025⟩. ⟨hal-04068529⟩
62 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More